Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
58 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Novavax, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Novavax, Inc. - Product Pipeline Review - 2014', provides an overview of the Novavax, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Novavax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Novavax, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Novavax, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Novavax, Inc.'s pipeline products Reasons to buy - Evaluate Novavax, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Novavax, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Novavax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Novavax, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novavax, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Novavax, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Novavax, Inc. Snapshot 5 Novavax, Inc. Overview 5 Key Information 5 Key Facts 5 Novavax, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Novavax, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Novavax, Inc. - Pipeline Products Glance 14 Novavax, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Novavax, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Novavax, Inc. - Drug Profiles 18 H1N1-2009 VLP Vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Quadrivalent Seasonal Influenza Virus-Like Particle Vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Respiratory Syncytial Virus Vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Trivalent Seasonal Influenza VLP Vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 H5N1 VLP Influenza Vaccine 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 H7N9 VLP Influenza Vaccine 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 E-Selectin Tolerogen 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 MERS-CoV Vaccine 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Respiratory Syncytical Virus Fusion + Seasonal Influenza Virus-Like Particle 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 SARS-CoV Vaccine 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Vaccine For Rabies 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Varicella Zoster Virus Vaccine 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Novavax, Inc. - Pipeline Analysis 35 Novavax, Inc. - Pipeline Products by Target 35 Novavax, Inc. - Pipeline Products by Route of Administration 36 Novavax, Inc. - Pipeline Products by Molecule Type 37 Novavax, Inc. - Recent Pipeline Updates 38 Novavax, Inc. - Dormant Projects 48 Novavax, Inc. - Company Statement 49 Novavax, Inc. - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 57 Methodology 57 Coverage 57 Secondary Research 57 Primary Research 57 Expert Panel Validation 57 Contact Us 58 Disclaimer 58
List of Tables Novavax, Inc., Key Information 5 Novavax, Inc., Key Facts 5 Novavax, Inc. - Pipeline by Indication, 2014 8 Novavax, Inc. - Pipeline by Stage of Development, 2014 9 Novavax, Inc. - Monotherapy Products in Pipeline, 2014 10 Novavax, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Novavax, Inc. - Partnered Products in Pipeline, 2014 12 Novavax, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 Novavax, Inc. - Phase II, 2014 14 Novavax, Inc. - Phase I, 2014 15 Novavax, Inc. - Preclinical, 2014 16 Novavax, Inc. - Discovery, 2014 17 Novavax, Inc. - Pipeline by Target, 2014 35 Novavax, Inc. - Pipeline by Route of Administration, 2014 36 Novavax, Inc. - Pipeline by Molecule Type, 2014 37 Novavax, Inc. - Recent Pipeline Updates, 2014 38 Novavax, Inc. - Dormant Developmental Projects,2014 48 Novavax, Inc., Other Locations 56 Novavax, Inc., Subsidiaries 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
